According to a recent LinkedIn post from FluoretiQ Limited, research covering 2,599 dogs and cats across 52 U.S. veterinary practices suggests a substantial gap between antibiotic prescribing and prior diagnostic testing. The post cites Journal of the American Veterinary Medical Association data indicating 29% of animals received antibiotics while only 13% underwent diagnostic tests first.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that conventional culture and sensitivity testing can take 24 to 72 hours, whereas veterinary consultations typically last about 15 minutes, implying that prescribing decisions are often made without timely lab results. According to the summary of the research, removing cost barriers to diagnostics and adding a decision-support tool reportedly reduced empirical prescribing and shortened treatment durations.
FluoretiQ’s LinkedIn commentary frames antibiotic stewardship in veterinary practice as an “information timing” issue rather than a values problem, positioning faster diagnostics as a potential solution. In this context, the company references its Veri-5 Vet product, described as identifying common urinary pathogens in about 15 minutes so that results can be available during the consultation.
For investors, the post suggests a growing market opportunity in point-of-care veterinary diagnostics linked to antimicrobial stewardship and regulatory or professional pressure to limit unnecessary antibiotic use. If adopted at scale, rapid-testing platforms like Veri-5 Vet could drive recurring product and consumables revenue, enhance FluoretiQ’s competitive position in veterinary medicine, and potentially support premium pricing based on clinical workflow and stewardship benefits.